TY - JOUR
T1 - Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection
T2 - A downward spiral in kidney disease
AU - Dusso, Adriana S.
AU - Tokumoto, Masanori
N1 - Funding Information:
This work was supported in part by grants to ASD from the National Institutes of Health (DK062713), from the Center for D-receptor Activation Research, Massachusetts General Hospital, Boston, MA, USA, and from Abbott Laboratories, as well as by a Washington University grant for Research in Renal Disease to Dr Slatopolsky. We thank Dr Dan Coyne for valuable discussions on the current clinical recommendations for active vitamin D therapy in kidney disease, and Dr Maria Vittoria Arcidiacono for her assistance in the design of figures.
PY - 2011/4
Y1 - 2011/4
N2 - In kidney disease, the progressive loss of renal capacity to produce calcitriol, the vitamin D hormone, is a key contributor to elevations in parathyroid hormone (PTH) and mineral and skeletal disorders predisposing to renal and cardiovascular damage, ectopic calcifications, and high mortality rates. Thus, the safe correction of calcitriol deficiency to suppress PTH has been the treatment of choice for decades. However, recent epidemiological and experimental data suggest that calcitriol replacement may improve outcomes through renal and cardioprotective actions unrelated to PTH suppression. Furthermore, a striking incidence of vitamin D deficiency occurs in kidney disease and associates more strongly than calcitriol deficiency with a higher risk for kidney disease progression and death. Despite the translational relevance of these findings, no prospective trials are currently available in support of the efficacy of vitamin D supplementation and/or calcitriol replacement to safely halt/moderate renal disease progression. This review updates the pathophysiology behind the vicious cycle by which kidney injury impairs the maintenance of normal vitamin D and calcitriol levels, which in turn impedes vitamin D/calcitriol renoprotective actions, a requirement for the design of prospective trials to improve current recommendations for vitamin D interventions at all stages of kidney disease.
AB - In kidney disease, the progressive loss of renal capacity to produce calcitriol, the vitamin D hormone, is a key contributor to elevations in parathyroid hormone (PTH) and mineral and skeletal disorders predisposing to renal and cardiovascular damage, ectopic calcifications, and high mortality rates. Thus, the safe correction of calcitriol deficiency to suppress PTH has been the treatment of choice for decades. However, recent epidemiological and experimental data suggest that calcitriol replacement may improve outcomes through renal and cardioprotective actions unrelated to PTH suppression. Furthermore, a striking incidence of vitamin D deficiency occurs in kidney disease and associates more strongly than calcitriol deficiency with a higher risk for kidney disease progression and death. Despite the translational relevance of these findings, no prospective trials are currently available in support of the efficacy of vitamin D supplementation and/or calcitriol replacement to safely halt/moderate renal disease progression. This review updates the pathophysiology behind the vicious cycle by which kidney injury impairs the maintenance of normal vitamin D and calcitriol levels, which in turn impedes vitamin D/calcitriol renoprotective actions, a requirement for the design of prospective trials to improve current recommendations for vitamin D interventions at all stages of kidney disease.
KW - renal damage
KW - serum markers of renal lesions
KW - vitamin D metabolism
KW - vitamin D receptor activation
KW - vitamin D supplementation
UR - http://www.scopus.com/inward/record.url?scp=79952709139&partnerID=8YFLogxK
U2 - 10.1038/ki.2010.543
DO - 10.1038/ki.2010.543
M3 - Article
C2 - 21270766
AN - SCOPUS:79952709139
SN - 0085-2538
VL - 79
SP - 715
EP - 729
JO - Kidney International
JF - Kidney International
IS - 7
ER -